AVEO Oncology, also known as AVEO Pharmaceuticals, Inc., has begun to enrol patients in a Phase III clinical trial evaluating its candidate ficlatuzumab in combination with Erbitux (cetuximab) in patients with human papillomavirus (HPV)-negative recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), marking the first R&D milestone after the company's integration with South Korea's LG Chem, Ltd.
Under LG Chem’s Wing, AVEO Oncology Steps On R&D Gas Pedal
Ficlatuzumab Combo Enters Phase III
With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.
